Carib A. Oquendo

Array ( [id] => 6420268 [patent_doc_number] => 20100150925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-17 [patent_title] => 'TREATMENT OF B-CELL CANCERS WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 12/635571 [patent_app_country] => US [patent_app_date] => 2009-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39944 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0150/20100150925.pdf [firstpage_image] =>[orig_patent_app_number] => 12635571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10627646 [patent_doc_number] => 09345785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates' [patent_app_type] => utility [patent_app_number] => 12/635607 [patent_app_country] => US [patent_app_date] => 2009-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 39926 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12635607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6391989 [patent_doc_number] => 20100303817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-02 [patent_title] => 'ANTIBODIES TO TREAT CANCER' [patent_app_type] => utility [patent_app_number] => 12/633498 [patent_app_country] => US [patent_app_date] => 2009-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19977 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0303/20100303817.pdf [firstpage_image] =>[orig_patent_app_number] => 12633498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7762399 [patent_doc_number] => 08114846 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-02-14 [patent_title] => 'Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors' [patent_app_type] => utility [patent_app_number] => 12/631116 [patent_app_country] => US [patent_app_date] => 2009-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 77583 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/114/08114846.pdf [firstpage_image] =>[orig_patent_app_number] => 12631116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7493676 [patent_doc_number] => 20110239316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-29 [patent_title] => 'ANTI-cMET ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/132211 [patent_app_country] => US [patent_app_date] => 2009-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 25236 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0239/20110239316.pdf [firstpage_image] =>[orig_patent_app_number] => 13132211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6430127 [patent_doc_number] => 20100143290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-10 [patent_title] => 'MONOCLONAL ANTIBODIES TO HUMAN THYMIDINE KINASE TO TREAT CANCER' [patent_app_type] => utility [patent_app_number] => 12/629795 [patent_app_country] => US [patent_app_date] => 2009-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 12668 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0143/20100143290.pdf [firstpage_image] =>[orig_patent_app_number] => 12629795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6497568 [patent_doc_number] => 20100093980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-15 [patent_title] => 'Methods of Humanizing Immunoglobulin Variable Regions Through Rational Modification Of Complementarity Determining Residues' [patent_app_type] => utility [patent_app_number] => 12/628898 [patent_app_country] => US [patent_app_date] => 2009-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 28661 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0093/20100093980.pdf [firstpage_image] =>[orig_patent_app_number] => 12628898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7560854 [patent_doc_number] => 20110274686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND MELPHALAN' [patent_app_type] => utility [patent_app_number] => 13/130862 [patent_app_country] => US [patent_app_date] => 2009-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4999 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0274/20110274686.pdf [firstpage_image] =>[orig_patent_app_number] => 13130862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6313712 [patent_doc_number] => 20100111856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-06 [patent_title] => 'ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES' [patent_app_type] => utility [patent_app_number] => 12/612912 [patent_app_country] => US [patent_app_date] => 2009-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 40702 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0111/20100111856.pdf [firstpage_image] =>[orig_patent_app_number] => 12612912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7669070 [patent_doc_number] => 20110318339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-29 [patent_title] => 'ANTI-DLL4 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/128236 [patent_app_country] => US [patent_app_date] => 2009-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 77699 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13128236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6380043 [patent_doc_number] => 20100316630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'ANTI-IDIOTYPE ANTIBODIES OF THE HUMAN MONOCLONAL ANTIBODY SC-1, AND THEIR PRODUCTION AND USE' [patent_app_type] => utility [patent_app_number] => 12/611824 [patent_app_country] => US [patent_app_date] => 2009-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7496 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0316/20100316630.pdf [firstpage_image] =>[orig_patent_app_number] => 12611824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6245761 [patent_doc_number] => 20100136033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-06-03 [patent_title] => 'METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES' [patent_app_type] => utility [patent_app_number] => 12/609737 [patent_app_country] => US [patent_app_date] => 2009-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 28988 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0136/20100136033.pdf [firstpage_image] =>[orig_patent_app_number] => 12609737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5985546 [patent_doc_number] => 20110097747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-28 [patent_title] => 'Monoclonal antibody binds antigen associated with human tumors' [patent_app_type] => utility [patent_app_number] => 12/589588 [patent_app_country] => US [patent_app_date] => 2009-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5701 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0097/20110097747.pdf [firstpage_image] =>[orig_patent_app_number] => 12589588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12408594 [patent_doc_number] => 09969797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Immunoglobulins directed to bacterial, viral and endogenous polypeptides [patent_app_type] => utility [patent_app_number] => 12/589440 [patent_app_country] => US [patent_app_date] => 2009-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 94 [patent_no_of_words] => 22686 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12589440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6581030 [patent_doc_number] => 20100291072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-18 [patent_title] => 'ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION RATES' [patent_app_type] => utility [patent_app_number] => 12/581574 [patent_app_country] => US [patent_app_date] => 2009-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21778 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20100291072.pdf [firstpage_image] =>[orig_patent_app_number] => 12581574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6632663 [patent_doc_number] => 20100173382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-08 [patent_title] => 'HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES' [patent_app_type] => utility [patent_app_number] => 12/580702 [patent_app_country] => US [patent_app_date] => 2009-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 31674 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0173/20100173382.pdf [firstpage_image] =>[orig_patent_app_number] => 12580702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6601691 [patent_doc_number] => 20100098730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'IMMUNOGLOBULIN VARIANTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 12/577967 [patent_app_country] => US [patent_app_date] => 2009-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 54866 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20100098730.pdf [firstpage_image] =>[orig_patent_app_number] => 12577967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8027399 [patent_doc_number] => 08142779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-03-27 [patent_title] => 'Treatment of follicular lymphomas using inhibitors of the LT pathway' [patent_app_type] => utility [patent_app_number] => 12/578016 [patent_app_country] => US [patent_app_date] => 2009-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8096 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/142/08142779.pdf [firstpage_image] =>[orig_patent_app_number] => 12578016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6314301 [patent_doc_number] => 20100111967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-06 [patent_title] => 'BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 12/572289 [patent_app_country] => US [patent_app_date] => 2009-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 37039 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0111/20100111967.pdf [firstpage_image] =>[orig_patent_app_number] => 12572289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6600909 [patent_doc_number] => 20100098692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'Humanized Endoglin Antibodies' [patent_app_type] => utility [patent_app_number] => 12/570918 [patent_app_country] => US [patent_app_date] => 2009-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 68392 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20100098692.pdf [firstpage_image] =>[orig_patent_app_number] => 12570918 [rel_patent_id] =>[rel_patent_doc_number] =>)